SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Altimmune, Inc. following a significant decline in its stock price after the announcement of disappointing trial results for Pemvidutide [4][6][7] Group 1: Legal Investigation - Faruqi & Faruqi is encouraging investors who suffered losses in Altimmune to contact them to discuss legal options [1] - The firm has set an October 6, 2025 deadline for investors to seek the role of lead plaintiff in a federal securities class action against Altimmune [4] - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5] Group 2: Trial Results and Stock Impact - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [6] - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [7]